|
Contraindications
Myeloid malignancies. Lactation.
|
|
Special Precautions
Patients with any pre-malignant or malignant myeloid condition, pre-existing pulmonary disease. Discontinue use in patients who develop signs of pulmonary infiltrates. Patients with fluid retention or heart failure. Regularly monitor CBC during therapy. Pregnancy.
|
|
Adverse Reactions
Fever and chills, nausea, dyspnoea, diarrhoea, rash, rigors, inj site reaction (SC admin), vomiting, fatigue, anorexia, bone and musculoskeletal pain, asthenia, transient hypotension, non-specific chest pain, stomatitis, headache, increased sweating, abdominal pain, pruritus, dizziness, peripheral oedema, paraesthesia and myalgia. Antibodies can develop.
Potentially Fatal: Anaphylactic reactions, pleural and pericardial effusion, cardiac arrhythmias. |
|
Drug Interactions
May increase occurrence of bleomycin-induced pulmonary toxicity.
|
|
CIMS Class
|
|
ATC Classification
L03AA03 - molgramostim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
|
Sign Out
